ELISA/ACT Biotechnologies
Business Services · Virginia, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
109 Carpenter Dr Ste 100, Sterling, Virg...Phone Number
(703) 450-2980Website
www.elisaact.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
4
1
1
1
1
About ELISA/ACT Biotechnologies
ELISA/ACT Biotechnologies (EAB) has been a leader in personalized immunology since 1984, specializing in the Lymphocyte Response Assay (LRA) for testing delayed hypersensitivities. Their innovative testing has helped clinicians identify hidden immune triggers linked to chronic conditions, enhancing patient care and quality of life. Although EAB has decided to discontinue its operations, it continues to support the community through its sister company, PERQUE Integrative Health, which offers science-based nutritional solutions. EAB remains committed to integrative health and the legacy of Dr. Russell M. Jaffe.Explore more
ELISA/ACT Biotechnologies Org Chart
GB
Special Event Specialist
AH
Account Executive
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is ELISA/ACT Biotechnologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if ELISA/ACT Biotechnologies has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once ELISA/ACT Biotechnologies has new funding data
Earning: See what the market has to say on ELISA/ACT Biotechnologies recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if ELISA/ACT Biotechnologies is spiking on competitors!
Product Launch: Get notified when ELISA/ACT Biotechnologies launches new products
ELISA/ACT Biotechnologies, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if ELISA/ACT Biotechnologies had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at ELISA/ACT Biotechnologies
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to ELISA/ACT Biotechnologies
Compare insights from companies similar to ELISA/ACT Biotechnologies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
ELISA/ACT Biotechnologies is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ELISA/ACT Biotechnologies is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ELISA/ACT Biotechnologies.
ELISA/ACT Biotechnologies financials insights
Gather financial insights about ELISA/ACT Biotechnologies, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$150K
ELISA/ACT Biotechnologies Tech Stack
A closer look at the technologies used by ELISA/ACT Biotechnologies
Top Business Services Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding ELISA/ACT Biotechnologies
Sign Up For FreeTo access detailed company insights
ELISA/ACT Biotechnologies (EAB) has been a leader in personalized immunology since 1984, specializing in the Lymphocyte Response Assay (LRA) for testing delayed hypersensitivities. Their innovative testing has helped clinicians identify hidden immune triggers linked to chronic conditions, enhancing patient care and quality of life. Although EAB has... Read More
